Last reviewed · How we verify

Nicorette — Competitive Intelligence Brief

Nicorette (NICOTINE) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholinergic Nicotinic Agonist [EPC]. Area: Metabolic.

marketed Cholinergic Nicotinic Agonist [EPC] Neuronal acetylcholine receptor; alpha4/beta2 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Nicorette (NICOTINE) — Sanofi.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Nicorette TARGET NICOTINE Sanofi marketed Cholinergic Nicotinic Agonist [EPC] Neuronal acetylcholine receptor; alpha4/beta2 1991-01-01
Chantix varenicline Pfizer marketed Cholinergic Receptor Agonist Neuronal acetylcholine receptor; alpha4/beta2 2006-01-01
Champix Champix The Queen Elizabeth Hospital marketed Neuronal acetylcholine receptor subunit alpha-7, Neuronal acetylcholine receptor; alpha3/beta4, Neuronal acetylcholine receptor; alpha4/beta2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cholinergic Nicotinic Agonist [EPC] class)

  1. Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nicorette — Competitive Intelligence Brief. https://druglandscape.com/ci/nicotine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: